Novavax, Inc. (NASDAQ:NVAX) traded at $236.93 at close of the session on Monday, May 03, made a downturn move of -0.25% on its previous day’s price.
Looking at the stock we see that its previous close was $237.53 and the beta (5Y monthly) reads 1.54 with the day’s price range being $235.11 – 249.45. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, NVAX has a high of $331.68 and a low of $16.41. The company’s stock has gained about 30.68% over that past 30 days.
Novavax, Inc. has a market cap of $17.54 Billion and is expected to release its quarterly earnings report on May 10, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the NVAX stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$2.65, with the EPS growth for the year raised at $16.11 for 2021 and $32.84 for next year. These figures represent -3.22% and 1.04% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $291.87 Million, with a low of $150Million and a high of $433.1 Million. The median projection represents growth adding up to 8542.9% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $3.81 Billion, or +701.9% up from figures reported last year.
On the other hand, looking at the outlook for the NVAX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Novavax, Inc. (NVAX) stock as a Hold, while 5 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the NVAX stock currently stands at 0, and the current price level is 15.88% off its SMA20 and 14.75% from its 50-day simple moving average. The RSI (14) is pointing at 59.25 while the volatility over the past week is 1065% and drops to 8.13% over the past one month. The beta value is 1.54, while the average true range (ATR) is currently pointing at 18.98. The average price target for the stock over the next 12 months is $323, with the estimates having a low of $285 and a high of $365. These price ends are 20.29% and +54.05% off the current price level respectively, although investors could be excited at the prospect of a +33.79% if the NVAX share price touches on the median price of $317.
Let’s briefly compare Novavax, Inc. (NVAX) stock to its peers. We find that current price change of -0.25% and +1206.84% over the past 12 months for NVAX betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.75% in the last trading session and was +2.65% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 2.1% previous session, and was +0.18% up over the past year, while Gilead Sciences Inc (GILD) was also down -0.25% in the last session, while its price remained in the green at 1206.84% over the same period. Novavax, Inc. has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.85. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.72% and -0.54%, respectively, at close of the trading.
Coming back to Novavax, Inc. (NASDAQ:NVAX), we note that the average 3-month trading volume was 4.47 Million, while that of the preceding 10-day period stands at 2.3 Million. Current shares outstanding are 73.86 Million.
According to data from Thomson Reuters, insiders hold 0.37% of the company’s shares while institutions hold 55.04%. The data shows that short shares as of April 14, 2021, stood at 4.7 Million at a short ratio of 1.64. This represents a 6.36% short interest in shares outstanding on April 14, 2021. Shares short dropped in April from the previous month at 4.95 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +112.47% up in year-to-date price movement.